Skip to main content

Advertisement

SpringerLink
Log in

Review of Sexual Health-Friendly BPH Therapies

  • Male and Female Surgical Interventions (A Baumgarten, Section Editor)
  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review serves to explore minimally invasive BPH therapies, with a focus on the sexual side effects of each given modality. The article seeks to give the reader a better understanding of the risk of erectile and ejaculatory dysfunction following various bladder outlet procedures and surgeries.

Recent Findings

Multiple urologic treatment technologies are entering the market and gaining FDA approval. UroLift®, Rezūm™, and Aquablation are now supported by the American Urological Association guidelines for the treatment of BPH-related LUTS. Each modality has a relatively low risk of erectile or ejaculatory dysfunction when compared to traditional transurethral resection of the prostate (TURP). Other treatment options, such as prostatic arterial embolization and the Temporarily Implanted Nitinol Device (iTind), may edge their way toward standard of care as new evidence regarding safety and efficacy becomes available.

Summary

Various treatment modalities have been proven to be safe when considering a bladder outlet procedure. Depending on the patient’s prostatic size, anatomy, and his goals of care, clinicians should be able to offer a BPH treatment option with a favorable prognosis as well as an acceptable risk profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. J Urol. 2021;206(4):806–17. https://doi.org/10.1097/JU.0000000000002183.

    Article  PubMed  Google Scholar 

  2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9. https://doi.org/10.1016/s0022-5347(17)49698-4.

    Article  CAS  PubMed  Google Scholar 

  3. Suarez-Ibarrola R, Miernik A, Gratzke C, Schoeb DS. Reasons for new MIS. Let’s be fair: iTIND, Urolift and Rezum. World J Urol. 2021;39(7):2315–27. https://doi.org/10.1007/s00345-020-03453-z.

  4. Das AK, Han TM, Uhr A, Roehrborn CG. Benign prostatic hyperplasia: an update on minimally invasive therapy including Aquablation. Can J Urol. 2020;27(S3):2–10.

    PubMed  Google Scholar 

  5. Leong JY, Patel AS, Ramasamy R. Minimizing sexual dysfunction in BPH surgery. Curr Sex Health Rep. 2019;11(3):190–200. https://doi.org/10.1007/s11930-019-00210-1.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Press release: Teleflex announces FDA clearance for expanded indication of the UroLift® system for treatment of larger prostates, up to 100cc. 2020. https://www.urolift.com/press-releases/fda-expanded-indication-up-to-100cc. Accessed June 25 2022.

  7. Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis. 2019;22(3):411–9. https://doi.org/10.1038/s41391-018-0118-x.

    Article  PubMed  Google Scholar 

  8. Annese P, d’Altilia N, Mancini V, Falagario UG, Del Giudice F, Ferro M, et al. Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center. Ther Adv Urol. 2021;13:17562872211037108. https://doi.org/10.1177/17562872211037109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol. 2019;37(7):1353–60. https://doi.org/10.1007/s00345-018-2494-1.

    Article  PubMed  Google Scholar 

  10. Beilan J WJ, Emtage J, Moscowitz A, Ortega-Vilches A, Bickell M, Parker J, Hernandez DJ, Carrion RE, Perito P, editor. Prostatic urethral lift offers relief in patients planning for penile prosthesis. WAMS 4th Congress for Medical Sexology; 2015 Oct 10, 2015; Miami, FL.

  11. Baboudjian M, Fourmarier M, Gondran-Tellier B, Pradere B, Userovici M, Alegorides C, et al. Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study. Int Urol Nephrol. 2021;53(9):1757–63. https://doi.org/10.1007/s11255-021-02899-3.

    Article  PubMed  Google Scholar 

  12. Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72(6):986–97. https://doi.org/10.1016/j.eururo.2017.07.005.

    Article  PubMed  Google Scholar 

  13. Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042–7. https://doi.org/10.1016/j.urology.2015.05.046.

    Article  PubMed  Google Scholar 

  14. Garden EB, Shukla D, Ravivarapu KT, Kaplan SA, Reddy AK, Small AC, et al. Rezum therapy for patients with large prostates (>/= 80 g): initial clinical experience and postoperative outcomes. World J Urol. 2021;39(8):3041–8. https://doi.org/10.1007/s00345-020-03548-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Siena G, Cindolo L, Ferrari G, Maruzzi D, Fasolis G, Condorelli SV, et al. Water vapor therapy (Rezum) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol. 2021;39(10):3875–80. https://doi.org/10.1007/s00345-021-03642-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ines M, Babar M, Singh S, Iqbal N, Ciatto M. Real-world evidence with the Rezum system: a retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes. Prostate. 2021;81(13):956–70. https://doi.org/10.1002/pros.24191.

    Article  CAS  PubMed  Google Scholar 

  17. McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206(3):715–24. https://doi.org/10.1097/JU.0000000000001778.

    Article  PubMed  Google Scholar 

  18. Product instructions: Rezūm™ Delivery Device Kit for BPH Boston Scientific. 2019. https://www.bostonscientific.com/content/dam/bostonscientific/uro-wh/portfolio-group/lithotripsy/rezum/50998296-01a_rezum_dfu_en_s.pdf. Accessed August 18 2022.

  19. Zorn KC, Bidair M, Trainer A, Arther A, Kramolowsky E, Desai M, et al. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass. 2022;3(2):130–8. https://doi.org/10.1002/bco2.121.

    Article  PubMed  Google Scholar 

  20. Bach T, Gilling P, El Hajj A, Anderson P, Barber N. First multi-center all-comers study for the aquablation procedure. J Clin Med. 2020;9(2). https://doi.org/10.3390/jcm9020603.

  21. Bhojani N, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, et al. Aquablation for benign prostatic hyperplasia in large prostates (80–150 cc): 1-year results. Urology. 2019;129:1–7. https://doi.org/10.1016/j.urology.2019.04.029.

    Article  PubMed  Google Scholar 

  22. Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Three-year outcomes after aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020;27(1):10072–9.

    PubMed  Google Scholar 

  23. Yee CH, Tang SF, Yuen SK, Chan CK, Teoh JYC, Chiu PKF, et al. Technique, outcome and changes in prostate dimensions in patients with urinary retention managed by aquablation. Int Urol Nephrol. 2022. https://doi.org/10.1007/s11255-022-03244-y.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Xu Z, Zhou Z, Mu Y, Cai T, Gao Z, Liu L. An updated meta-analysis of the efficacy and safety of prostatic artery embolization vs. transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. Front Surg. 2021;8:779571. https://doi.org/10.3389/fsurg.2021.779571.

  25. Abt D, Schmid HP, Speakman MJ. Reasons to consider prostatic artery embolization. World J Urol. 2021;39(7):2301–6. https://doi.org/10.1007/s00345-021-03601-z.

    Article  PubMed  Google Scholar 

  26. Marzano L, Thiounn N, Pereira H, Pellerin O, Dariane C, Del Giudice C, et al. Prostatic artery embolization allows to maintain full sexual activity in patients suffering from bothersome lower urinary tracts symptoms related to benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2020;43(8):1202–7. https://doi.org/10.1007/s00270-020-02520-7.

    Article  PubMed  Google Scholar 

  27. Mullhaupt G, Hechelhammer L, Diener PA, Engeler DS, Gusewell S, Schmid HP, et al. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World J Urol. 2020;38(10):2595–9. https://doi.org/10.1007/s00345-019-03036-7.

    Article  PubMed  Google Scholar 

  28. Bilhim T, Costa NV, Torres D, Pisco J, Carmo S, Oliveira AG. Randomized clinical trial of balloon occlusion versus conventional microcatheter prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol. 2019;30(11):1798–806. https://doi.org/10.1016/j.jvir.2019.06.019.

    Article  PubMed  Google Scholar 

  29. Kadner G, Valerio M, Giannakis I, Manit A, Lumen N, Ho BSH, et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. 2020;38(12):3235–44. https://doi.org/10.1007/s00345-020-03140-z.

    Article  CAS  PubMed  Google Scholar 

  30. Elterman D, Gao B, Zorn KC, Bhojani N, Chughtai B. How I do it: temporarily implanted nitinol device (iTind). Can J Urol. 2021;28(4):10788–93.

    PubMed  Google Scholar 

  31. Amparore D, Fiori C, Valerio M, Schulman C, Giannakis I, De Cillis S, et al. 3-year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2021;24(2):349–57. https://doi.org/10.1038/s41391-020-00281-5.

    Article  CAS  PubMed  Google Scholar 

  32. De Nunzio C, Cantiello F, Fiori C, Crocerossa F, Tognoni P, Amparore D, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. World J Urol. 2021;39(6):2037–42. https://doi.org/10.1007/s00345-020-03418-2.

    Article  CAS  PubMed  Google Scholar 

  33. The ProVerum First in Man PROVE Study. U.S. National Library of Medicine. 2019. https://clinicaltrials.gov/ct2/show/study/NCT03972371. Accessed July 7 2022.

  34. ProVerum: first enrolment in the ProVIDE clinical study for BPH treatment. PR Newswire. 2022. https://www.prnewswire.com/news-releases/proverum-first-enrolment-in-the-provide-clinical-study-for-bph-treatment-301566430.html. Accessed July 7 2022.

Download references

Author information

Authors and Affiliations

  1. Advanced Urology Institute, Largo, FL, USA

    Nicholas Zulia & Jonathan Beilan

Authors
  1. Nicholas Zulia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Beilan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan Beilan.

Ethics declarations

Dr. Beilan is a consultant to Boston Scientific Corporation, menMD, Inc., and Bastion Health. The authors received no financial during the planning, implementation, writing, peer review, editing, and publication of this scientific work.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Male and Female Surgical Interventions

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zulia, N., Beilan, J. Review of Sexual Health-Friendly BPH Therapies. Curr Sex Health Rep 14, 135–139 (2022). https://doi.org/10.1007/s11930-022-00344-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-022-00344-9

Keywords

Search

Navigation